India's National Pharmaceutical Pricing Authority (NPPA) has exempted Sun Pharmaceutical's chemotherapy drug gemcitabine from price controls, reported livemint.com.
According to the news source, the NPPA can exempt drugs from price controls if they are either new or have a new delivery system that is developed through "indigenous research."
The Standing National Committee on Medicines has raised concerns that there was no clinical study to suggest that Sun Pharma's gemcitabine offered significant therapeutic advantages and increased efficacy versus other forms of the drug.
However, the NPPA pointed out that increased therapeutic advantage and efficacy were not pre-conditions for granting price control exemptions for new drugs.
According to the NPPA website, Sun Pharma sells gemcitabine 200-mg powder for injection for INR 1231.65 per pack.
To read more NewsPoints articles, click here.